Lidocaine Hydrochloride and Dextrose NDC 84549-594

NDC codes

FDA NDC Directory

Product NDC (as listed)84549-594Labeler and product segments. Claims need a package NDC.

Product NDC at billing width84549-0594Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
84549-594-20	84549059420	250 mL in 1 CONTAINER (84549-594-20)Marketed from Jan 19, 2026

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Lidocaine Hydrochloride and Dextrose
Generic name (nonproprietary): lidocaine hydrochloride anhydrous and dextrose monohydrate
Active ingredients: Lidocaine hydrochloride anhydrous — .4 g/100mLDextrose monohydrate — 5 g/100mL
Dosage form: Injection, Solution
Route: Intravenous
Labeler: ProPharma Distribution
Product type: Prescription drug
Marketing category: NDA — New Drug ApplicationApplication NDA 019830
Marketing start: Apr 8, 1992
Listing expires: Dec 31, 2027
Other FDA classes: Amides (Chemical structure)Local Anesthesia (Physiologic effect)
Identifiers: Product ID 84549-594_48c0ee87-f723-1a71-e063-6394a90a72d1SPL ID 48c0ee87-f723-1a71-e063-6394a90a72d1SPL set ID 48c0ee87-f722-1a71-e063-6394a90a72d1RxCUI 1737742UNII EC2CNF7XFP, LX22YL083G
Pharmacologic class: Amide Local Anesthetic; Antiarrhythmic

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N484549059420 followed by a unit qualifier and the quantity

Package 84549-0594-20. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Jan 19, 2026.

Indications (excerpt from the label)

INDICATIONS AND USAGE Lidocaine hydrochloride administered intravenously is specifically indicated in the acute management of (1) ventricular arrhythmias occurring during cardiac manipulations, such as cardiac surgery and (2) life-threatening arrhythmias which are ventricular in origin, such as occur during acute myocardial infarction.

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under NDA 019830

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under NDA 019830
Product	Strength	Form · route	Labeler	Product NDC
Lidocaine Hydrochloride and Dextroselidocaine hydrochloride anhydrous and dextrose monohydrate	Lidocaine hydrochloride anhydrous .4 g/100mL; Dextrose monohydrate 5 g/100mL	Injection, SolutionIntravenous	B. Braun Medical Inc.	0264-9594
Lidocaine Hydrochloride and Dextroselidocaine hydrochloride anhydrous and dextrose monohydrate	Lidocaine hydrochloride anhydrous .8 g/100mL; Dextrose monohydrate 5 g/100mL	Injection, SolutionIntravenous	B. Braun Medical Inc.	0264-9598